NeOnc Technologies Holdings is trading at $3.30, up 7.84% in pre-market, with no newly reported company-specific announcement explaining the gain. - The September 28 announcement of a November 17 FDA meeting for NEO212 predates this move and does not establish a direct cause. - Supplied biotech-sector context is negative, while major U.S. index futures are modestly higher; neither clearly explains the stock-specific move. - The catalyst for the October 1 decline was also reported as unclear.